Ltr Pharma Stock Net Income
| LTP Stock | 0.49 0.02 3.92% |
As of the 8th of February, LTR Pharma secures the mean deviation of 3.57, and Risk Adjusted Performance of 0.0329. Concerning fundamental indicators, the technical analysis model lets you check available technical drivers of LTR Pharma, as well as the relationship between them.
LTR Pharma Total Revenue |
|
Gross Profit -1.3 M | Market Capitalization 89 M | Enterprise Value Revenue 392.6353 | Revenue | Earnings Share (0.03) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -6.3 M | -5.9 M | |
| Net Loss | -6.3 M | -5.9 M | |
| Net Loss | -5 M | -5.3 M |
LTR | Net Income |
The evolution of Net Income for LTR Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how LTR Pharma compares to historical norms and industry peers.
Latest LTR Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of LTR Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in LTR Pharma financial statement analysis. It represents the amount of money remaining after all of LTR Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is LTR Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LTR Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (6.95 M) | 10 Years Trend |
|
Net Income |
| Timeline |
LTR Net Income Regression Statistics
| Arithmetic Mean | (1,487,977) | |
| Coefficient Of Variation | (162.39) | |
| Mean Deviation | 1,930,922 | |
| Median | (40,803) | |
| Standard Deviation | 2,416,338 | |
| Sample Variance | 5.8T | |
| Range | 6.9M | |
| R-Value | (0.77) | |
| Mean Square Error | 2.6T | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (366,146) | |
| Total Sum of Squares | 93.4T |
LTR Net Income History
LTR Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LTR Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LTR Pharma.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in LTR Pharma on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding LTR Pharma or generate 0.0% return on investment in LTR Pharma over 90 days. LTR Pharma is related to or competes with Acorn Capital, Environmental, Air New, Steamships Trading, and Australian United. LTR Pharma is entity of Australia. It is traded as Stock on AU exchange. More
LTR Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LTR Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LTR Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.65 | |||
| Information Ratio | 0.0129 | |||
| Maximum Drawdown | 30.67 | |||
| Value At Risk | (7.27) | |||
| Potential Upside | 9.3 |
LTR Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LTR Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LTR Pharma's standard deviation. In reality, there are many statistical measures that can use LTR Pharma historical prices to predict the future LTR Pharma's volatility.| Risk Adjusted Performance | 0.0329 | |||
| Jensen Alpha | 0.0924 | |||
| Total Risk Alpha | (0.36) | |||
| Sortino Ratio | 0.0143 | |||
| Treynor Ratio | 0.2172 |
LTR Pharma February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0329 | |||
| Market Risk Adjusted Performance | 0.2272 | |||
| Mean Deviation | 3.57 | |||
| Semi Deviation | 3.75 | |||
| Downside Deviation | 4.65 | |||
| Coefficient Of Variation | 3293.44 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.36 | |||
| Information Ratio | 0.0129 | |||
| Jensen Alpha | 0.0924 | |||
| Total Risk Alpha | (0.36) | |||
| Sortino Ratio | 0.0143 | |||
| Treynor Ratio | 0.2172 | |||
| Maximum Drawdown | 30.67 | |||
| Value At Risk | (7.27) | |||
| Potential Upside | 9.3 | |||
| Downside Variance | 21.58 | |||
| Semi Variance | 14.05 | |||
| Expected Short fall | (5.07) | |||
| Skewness | 1.38 | |||
| Kurtosis | 4.36 |
LTR Pharma Backtested Returns
Currently, LTR Pharma is out of control. LTR Pharma has Sharpe Ratio of 0.0373, which conveys that the firm had a 0.0373 % return per unit of volatility over the last 3 months. We have found twenty-nine technical indicators for LTR Pharma, which you can use to evaluate the volatility of the firm. Please verify LTR Pharma's risk adjusted performance of 0.0329, and Mean Deviation of 3.57 to check out if the risk estimate we provide is consistent with the expected return of 0.19%. LTR Pharma has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.67, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, LTR Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding LTR Pharma is expected to be smaller as well. LTR Pharma presently secures a risk of 5.14%. Please verify LTR Pharma total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to decide if LTR Pharma will be following its current price movements.
Auto-correlation | -0.07 |
Very weak reverse predictability
LTR Pharma has very weak reverse predictability. Overlapping area represents the amount of predictability between LTR Pharma time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LTR Pharma price movement. The serial correlation of -0.07 indicates that barely 7.0% of current LTR Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.07 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
LTR Net Interest Income
Net Interest Income |
|
Based on the recorded statements, LTR Pharma reported net income of (6.95 Million). This is 102.04% lower than that of the Pharmaceuticals sector and 109.93% lower than that of the Health Care industry. The net income for all Australia stocks is 101.22% higher than that of the company.
LTR Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LTR Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LTR Pharma could also be used in its relative valuation, which is a method of valuing LTR Pharma by comparing valuation metrics of similar companies.LTR Pharma is currently under evaluation in net income category among its peers.
LTR Fundamentals
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.51) % | ||||
| Current Valuation | 57.24 M | ||||
| Shares Outstanding | 181.73 M | ||||
| Shares Owned By Insiders | 42.05 % | ||||
| Price To Book | 2.83 X | ||||
| Price To Sales | 59.03 X | ||||
| Revenue | 2.1 M | ||||
| Gross Profit | (1.28 M) | ||||
| EBITDA | (6.1 M) | ||||
| Net Income | (6.95 M) | ||||
| Total Debt | 700.57 K | ||||
| Book Value Per Share | 0.17 X | ||||
| Cash Flow From Operations | (5.09 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Beta | 4.57 | ||||
| Market Capitalization | 89.05 M | ||||
| Total Asset | 32.21 M | ||||
| Retained Earnings | (12.69 M) | ||||
| Working Capital | 2.94 M | ||||
| Net Asset | 32.21 M |
About LTR Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LTR Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LTR Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LTR Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for LTR Stock Analysis
When running LTR Pharma's price analysis, check to measure LTR Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LTR Pharma is operating at the current time. Most of LTR Pharma's value examination focuses on studying past and present price action to predict the probability of LTR Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LTR Pharma's price. Additionally, you may evaluate how the addition of LTR Pharma to your portfolios can decrease your overall portfolio volatility.